Literature DB >> 25108168

Targets of the humoral autoimmune response in multiple sclerosis.

Judith Fraussen1, Nele Claes1, Laura de Bock1, Veerle Somers2.   

Abstract

Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS) with heterogeneous clinical, genetic and pathophysiological characteristics. The establishment of reliable biomarkers for diagnosis, prognosis and treatment of MS has therefore proven to be very difficult. During the last decades, mounting evidence has been collected for the involvement of B cells and antibodies in MS pathogenesis. A wide variety of autoantibodies has been described in MS and these autoantibodies could be useful biomarkers for MS. Since demyelination is a key component of MS pathogenesis, myelin antigens were first investigated as primary targets of autoantibodies in MS. More recently, it became evident that the humoral autoimmune response is not restricted to myelin but is much more widespread throughout the brain. Autoantibodies are formed against different CNS cell types, including neurons, oligodendrocytes and astrocytes, and even immune cells, indicating the complex heterogeneity of the disease. In this review, we give an extensive overview of the known autoantibody targets in MS, not according to the traditional subdivision of myelin and non-myelin components but according to each of the affected cell types, including the most recently described target antigens.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Autoantigen; Biomarker; Multiple sclerosis

Mesh:

Substances:

Year:  2014        PMID: 25108168     DOI: 10.1016/j.autrev.2014.07.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  27 in total

1.  Anoctamin 2 identified as an autoimmune target in multiple sclerosis.

Authors:  Burcu Ayoglu; Nicholas Mitsios; Ingrid Kockum; Mohsen Khademi; Arash Zandian; Ronald Sjöberg; Björn Forsström; Johan Bredenberg; Izaura Lima Bomfim; Erik Holmgren; Hans Grönlund; André Ortlieb Guerreiro-Cacais; Nada Abdelmagid; Mathias Uhlén; Tim Waterboer; Lars Alfredsson; Jan Mulder; Jochen M Schwenk; Tomas Olsson; Peter Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

Review 2.  Genetic architectures of seropositive and seronegative rheumatic diseases.

Authors:  Yohei Kirino; Elaine F Remmers
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

Review 3.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

4.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

5.  Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells.

Authors:  Stephen D Skaper; Massimo Barbierato; Laura Facci; Mila Borri; Gabriella Contarini; Morena Zusso; Pietro Giusti
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

6.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

7.  A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients.

Authors:  M Pazhouhandeh; M-A Sahraian; S D Siadat; A Fateh; F Vaziri; F Tabrizi; F Ajorloo; A K Arshadi; E Fatemi; S Piri Gavgani; F Mahboudi; F Rahimi Jamnani
Journal:  Clin Exp Immunol       Date:  2018-01-25       Impact factor: 4.330

8.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

Review 9.  Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

Authors:  Johannes J Roggenbuck; Joseph Boucraut; Emilien Delmont; Karsten Conrad; Dirk Roggenbuck
Journal:  Ann Transl Med       Date:  2018-09

Review 10.  Role of B Cells in Multiple Sclerosis and Related Disorders.

Authors:  Giancarlo Comi; Amit Bar-Or; Hans Lassmann; Antonio Uccelli; Hans-Peter Hartung; Xavier Montalban; Per Solberg Sørensen; Reinhard Hohlfeld; Stephen L Hauser
Journal:  Ann Neurol       Date:  2020-11-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.